Liver Disease
Conference Coverage
Significant Benefit with Liver Transplantation in ACLF: CHANCE Study
The findings highlight “the inadequacy of current transplant allocation criteria for patients with ACLF 2 and 3,” said Dr. Rajiv Jalan.
Conference Coverage
‘Dramatic’ Phase 2 Results for Survodutide in MASH, Fibrosis
Fifty percent of patients on 2.4- and 6-mg doses experienced a statistically significant improvement in fibrosis without worsening of MASH.
Conference Coverage
Seladelpar Shows Clinically Meaningful Improvements in PBC
The 2-year analysis also showed that seladelpar, a first-in-class, orally active agent, was safe and well tolerated.
Conference Coverage
Tirzepatide Shows Improvements in MASH Resolution, Fibrosis
Tirzepatide also led to weight loss in patients.
Conference Coverage
Women with Autoimmune Liver Diseases Still Face Increased CVD Risks
Women with autoimmune hepatitis had a significantly higher cardiovascular risk compared to women without autoimmune hepatitis.
Conference Coverage
Intelligent Liver Function Testing Helps Detect, Diagnose Chronic Liver Disease
The iLFT platform uses an automated algorithm that analyzes standard liver function test results.
News from the FDA/CDC
FDA OKs Iqirvo, First-in-Class PPAR Treatment for Primary Biliary Cholangitis
Accelerated approval of Iqirvo for PBC was based on data from the phase 3 ELATIVE trial published last year.
Conference Coverage
FMT Could Prevent Recurrence of Hepatic Encephalopathy in Patients With Cirrhosis
Standard treatment with lactulose and rifaximin often results in a lack of patient response.
From the AGA Journals
FIB-4 Index Misclassifies Many Patients
Out of 2776 subjects classified as low-risk by FIB-4, 277 (10%) were reclassified as higher risk by liver stiffness measurements.